Comparing standard and high frame rate ultrasound for heart disease assessment
High Frame Rate Contrast Enhanced-ultrasound for the Assessment of Ischaemic Heart Disease
This study is testing if high frame rate ultrasound can give better images for diagnosing heart disease compared to standard ultrasound in people with coronary artery disease or those at low risk for it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London North West Healthcare NHS Trust Academic / other |
| Locations | 1 site (Harrow, Middx) |
| Trial ID | NCT03850015 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of high frame rate ultrasound imaging compared to standard ultrasound imaging in patients with coronary artery disease or those at low risk for heart disease. Participants will undergo imaging with two different ultrasound systems, capturing both standard and high frame rate images before and after the administration of a contrast agent and during pharmacological stress. The goal is to determine if high frame rate ultrasound provides additional diagnostic information that could improve heart disease assessment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed coronary artery disease or those assessed as low risk for coronary heart disease.
Not a fit: Patients with severe heart conditions, significant pulmonary disease, or those unable to undergo pharmacological stress may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of heart disease diagnosis and improve patient outcomes through better imaging techniques.
How similar studies have performed: While the use of high frame rate ultrasound is a relatively novel approach, similar studies have shown promising results in enhancing imaging techniques for cardiovascular assessment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria Either * Ability to give informed consent * age ≥18years and * confirmed inducible wall motion / perfusion abnormality on previous stress echocardiogram * known coronary artery disease - defined by presence of flow-limiting coronary stenosis(\>70% diameter stenosis) on coronary angiography. OR • patient who has been assessed as at low risk of having coronary heart disease Exclusion Criteria: * Inability to undertake pharmacological stress, ie previously known intolerance to dipyridamole; * Moderate or Severe aortic or mitral regurgitation or severe mitral stenosis; * Significant pulmonary disease like severe COPD or pulmonary fibrosis; * Atrial fibrillation; * Inability to provide informed consent; * Pregnancy and lactation; * Known allergy to Sonovue * Patients with second and third degree heart block, unless they have a pacemaker fitted * Systolic BP \< 90 * Known Myasthenia Gravis * Bronchial asthma
Where this trial is running
Harrow, Middx
- London North West University Healthcare NHS Trust — Harrow, Middx, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Roxy Senior, MD — London North West University Healthcare Nhs Trust
- Study coordinator: Emma Howard, MSc
- Email: emma.howard16@nhs.net
- Phone: +442088692547
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.